tbo-filgrastim
tbo-filgrastim is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including GRANIX. Available dosage form: injection, solution.
Drug Details
- Generic Name
- tbo-filgrastim
- Brand Names
- GRANIX
- Application Number
- BLA125294
- Sponsor
- Cephalon, LLC
- NDC Codes
- 4
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- FILGRASTIM
Indications and Usage
1 INDICATIONS AND USAGE GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )